These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17351724)

  • 1. Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis.
    Neumann H; Csepregi A; Sailer M; Malfertheiner P
    J Neurol; 2007 Jun; 254(6):816-7. PubMed ID: 17351724
    [No Abstract]   [Full Text] [Related]  

  • 2. Unmasking autoimmune hepatitis under immunomodulatory treatment of multiple sclerosis--not only beta interferon.
    von Kalckreuth V; Lohse AW; Schramm C
    Am J Gastroenterol; 2008 Aug; 103(8):2147-8; author reply 2148. PubMed ID: 18796115
    [No Abstract]   [Full Text] [Related]  

  • 3. Factors leading patients to discontinue multiple sclerosis therapies.
    Daugherty KK; Butler JS; Mattingly M; Ryan M
    J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.
    Pöllmann W; Erasmus LP; Feneberg W; Then Bergh F; Straube A
    Neurology; 2002 Aug; 59(4):636-9. PubMed ID: 12196668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
    Dhib-Jalbut S
    Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of interferon Beta and glatiramer acetate in multiple sclerosis.
    Goodin DS
    Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract]   [Full Text] [Related]  

  • 9. [Hepatitis induced by glatiramer acetate].
    Fernández Fernández N; Joao Matias D; Pisabarros Blanco C; Rodríguez Martín L; Aparicio Cabezudo M; Linares Torres P; Hernando Martín M; Olcoz Goñi JL
    Gastroenterol Hepatol; 2015 Apr; 38(4):280-1. PubMed ID: 25042243
    [No Abstract]   [Full Text] [Related]  

  • 10. Glatiramer acetate induced hepatotoxicity.
    Subramaniam K; Pavli P; Llewellyn H; Chitturi S
    Curr Drug Saf; 2012 Apr; 7(2):186-8. PubMed ID: 22873505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
    Zwibel HL;
    Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis.
    Duchini A
    Am J Gastroenterol; 2002 Mar; 97(3):767-8. PubMed ID: 11922585
    [No Abstract]   [Full Text] [Related]  

  • 13. Arthritis during interferon beta-1b treatment in multiple sclerosis.
    Altintas A; Alici Y; Melikoğlu M; Siva A
    Mult Scler; 2002 Dec; 8(6):534-6. PubMed ID: 12474998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.
    Schott E; Paul F; Wuerfel JT; Zipp F; Rudolph B; Wiedenmann B; Baumgart DC
    World J Gastroenterol; 2007 Jul; 13(26):3638-40. PubMed ID: 17659718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glatiramer acetate-induced hepatitis in a young female patient with multiple sclerosis.
    La Gioia S; Bacis G; Sonzogni A; Frigeni B; Conti MZ; Vedovello M; Rottoli M
    Mult Scler Relat Disord; 2014 Nov; 3(6):732-4. PubMed ID: 25891553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for multiple sclerosis.
    Tremlett H
    Neurology; 2002 Jun; 58(12):1868. PubMed ID: 12084903
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis.
    Rosa DJ; Matias Fde A; Cedrim SD; Machado RF; Sá AA; Silva VC
    An Bras Dermatol; 2011; 86(2):336-8. PubMed ID: 21603818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Autoimmune hepatitis in a patient with multiple sclerosis under treatment with glatiramer acetate].
    Arruti M; Castillo-Triviño T; de la Riva P; Martí-Massó JF; López de Munain A; Olascoaga J
    Rev Neurol; 2012 Aug; 55(3):190-2. PubMed ID: 22825980
    [No Abstract]   [Full Text] [Related]  

  • 19. No evidence for increased frequency of autoantibodies during interferon-beta1b treatment of multiple sclerosis.
    Kivisäkk P; Lundahl J; von Heigl Z; Fredrikson S
    Acta Neurol Scand; 1998 May; 97(5):320-3. PubMed ID: 9613562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lethal capillary leak syndrome after a single administration of interferon beta-1b.
    Niederwieser G
    Neurology; 2000 Apr; 54(7):1545-6. PubMed ID: 10751284
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.